Author's Words: Overview of Strategic Management and Corporate Practice in the United States, Chapter 1. Introduction, Main Contributions of the Biopharmaceutical Industry, Current Public Health Issues in the United States, Chapter 2. In the Early Days of the Pharmaceutical Industry Worldwide, Aspirin in Germany and Penicillin from the United Kingdom to the United States, Aspirin Discovery in Bayer, Germany, Penicillin Discovery in the United Kingdom , Pfizer from 1849-1939: Fermentation Innovator, Pfizer in the 1940s: Large-Scale Penicillin Manufacturer, Pfizer in the 1950s: New Pharmaceutical Company with Terramycin (R), Streptomycin Discovery by Waksman and Patented by Merck, Shift from Germany to the United Kingdom and United States: 1950 -1960s, Chapter 3. The Birth of Biotechnology , Slow Progress Despite Gene Splicing Technology Breakthrough, Breakthroughs from the Two Collaborators, Fear of the Unknown, The First Patents in the Recombinant DNA Area, Genentech Was Born, Chapter 4. Emergence of Biotechnology Firms in the 1970s-1990s, Threats of Young Competitors with New Knowledge, New Biotechnology Firms' Emergence in a Social Context: Response of Science Communities, Science Department at UCSF, UC Berkeley, and Stanford, New Biotechnology Firms' Emergence in the Legal Environment, Case Study 1: Genentech, The First Biotechnology Firm , Case Study 2: Amgen, The Second Biotechnology Company, Chapter 5. New Biotechnology Firms' Emergence from a Pharmaceutical Management Perspective, Case Study 3: Eli Lilly's Open Innovation, Early History of Eli Lilly, Case Study 4: Bristol-Myers Squibb (BMS) , Chapter 6. US Regulations on the Biopharmaceutical Industry and Their Impact, Drug Act Amendments of 1962: Scientific Evidence of Safety and Efficacy, Drug Price Competition and Patent Restoration Act of 1984 for Generic Drugs, The Orphan Drug Act of 1983 for Rare Diseases, Off-Label Prescribing Practice, The Prescription Drug User Fee Act (PDUFA) in 1992, Chapter 7. Law and Strategies: How Biopharma's Strategies Adapted in Response to U.S. Law Changes, Healthcare Spending in the United States: The Economics of Biosimilars, Law Changes Since 2009, Implications of the Biologics Price Competition and Innovation Act (BPCIA) , Biologics: New Business Models, Dogfight 1: AbbVie's Humira (R) versus Amgen's Amjevita (R), Dogfight 2: AbbVie's Humira (R) versus Samsung Bioepis Co.'s Imraldi (R), Dogfight 3: Johnson & Johnson's Remicade (R) versus Samsung's Renflexis (R), The Future of Biosimilars, AbbVie: Best Strategist with Innovative Drugs, Generic Brands: Now Very Important Business Models, Chapter 8. Opportunistic Business Models in the Generic Drug Market, Mylan: The Path to Becoming a Giant Generic Drug Company, Unanticipatedly Strong Patents Defense of Bristol Myers Squibb, Turing Pharmaceutical: Too Opportunistic, Yet Legal Business Model, Chapter 9. Low Productivity of Drug Companies, Steep Rising Cost of Drugs as Strict Regulations Occurred, Low Productivity in Terms of New Drugs Approval, Chapter 10. Payers, Purchasers, and Promotions, Who Pays for Medicines in the United States, Direct-To-Consumer Advertising for Medicines, Food and Drug Administration, Case Study 5: The Path of Merck, The Unforgettable Mistake by Merck: Vioxx (R), Chapter 11. Innovation Capabilities, Innovation from a Dynamic Capabilities Perspective, R&D Capabilities: Patents, Publications, and Alliances, Chapter 12. Immuno-cancer Therapy, Immuno-cancer Therapy: BMS versus Merck, Case Study 6: Gilead Sciences, Inc. , Case Study 7: Kite Pharma, Current Achievements in CAR-T Cell Therapy: Novartis versus. Gilead Sciences, New Business Models for CAR-T Cell Therapies, Chapter 13. The Biopharmaceutical Industry in the Future, High Expectations in Personalized Medicines, Emerging Markets, The Impact of Visionary and Strategic Leadership, New Business Models, Conclusion, Index
